DICE Therapeutics Overview

  • Founded
  • 2013

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 90

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.4B

  • Investors
  • 15

DICE Therapeutics General Information

Description

DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.

Contact Information

Website
www.dicetherapeutics.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Parent Company
Eli Lilly
Primary Office
  • 400 East Jamie Court
  • Suite 300
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DICE Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 09-Aug-2023 $2.4B 00000 00.000 Completed Generating Revenue
8. IPO 15-Sep-2021 00000 00000 00000 Completed Generating Revenue
7. Later Stage VC (Series C1) 21-Aug-2021 0000 00000 00000 Completed Pre-Clinical Trials
6. Debt - General 13-Apr-2021 00.00 00000 Completed Pre-Clinical Trials
5. Later Stage VC (Series C) 08-Jan-2021 0000 00000 Completed Pre-Clinical Trials
4. Later Stage VC (Series B) 11-Jul-2018 000.00 0000 Completed Pre-Clinical Trials
3. Early Stage VC 16-Mar-2016 0000 000.00 Completed Pre-Clinical Trials
2. Early Stage VC 18-Jun-2015 $4M $7.5M Completed Pre-Clinical Trials
1. Early Stage VC 01-Jan-2014 $3.5M $3.5M 000.00 Completed Pre-Clinical Trials
To view DICE Therapeutics’s complete valuation and funding history, request access »

DICE Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series S-1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view DICE Therapeutics’s complete cap table history, request access »

DICE Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of n
Drug Discovery
South San Francisco, CA
90 As of 2023
00000
0.000 0000-00-00
000000&0 00000

000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000 000000000
Waltham, MA
000 As of 0000
00000
000000000 00000

000000

it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
0000000000000
San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DICE Therapeutics Competitors (173)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Morphic Therapeutic Formerly VC-backed Waltham, MA 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
00000000 000000000 Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
You’re viewing 5 of 173 competitors. Get the full list »

DICE Therapeutics Patents

  • 25

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

DICE Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022232625-A1 Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof Pending 10-Mar-2021
CA-3211505-A1 Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof Pending 10-Mar-2021
EP-3464590-A1 Methods of routing, compositions and uses thereof Inactive 05-Jun-2016 00000000000
EP-3464590-A4 Methods of routing, compositions and uses thereof Inactive 05-Jun-2016 00000000000 0
JP-2019523646-A Route determination methods, compositions, and uses thereof Pending 05-Jun-2016 B01J19/0046
To view DICE Therapeutics’s complete patent history, request access »

DICE Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Scott Robertson Chief Financial Officer
John Jacobsen Ph.D Chief Scientific Officer
Katie Soo Chief Business Officer
Pehr Harbury Ph.D Co-Founder & Board Member
Tim Lu Ph.D Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

DICE Therapeutics Board Members (12)

Name Representing Role Since
James Scopa JD Self Board Member 000 0000
Lisa Bowers Self Board Member 000 0000
Michael Rubin MD Northpond Ventures Board Member 000 0000
Mittie Doyle MD Self Board Member 000 0000
Pehr Harbury Ph.D DICE Therapeutics Co-Founder & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

DICE Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DICE Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Agent Capital Venture Capital Minority 000 0000 000000 0
Northpond Ventures Venture Capital Minority 000 0000 000000 0
Osage University Partners Venture Capital Minority 000 0000 000000 0
To view DICE Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial